



## **Prostatype Genomics AB**

Org. 556726-0285

## **Quartely report Q1 2022**

1 January 2022 – 31 March 2022

## Quarter 1 (1 March – 31 March 2022) summarized

- Net sales amounted to 264 TSEK.
- Net revenue amounted to 260 TSEK.
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to – 5 050 TSEK.
- Cash flow from current operations in the quarter amounted -5 802 TSEK.
- Total cash flow for the period amounted to -5 903 TSEK.
- Earnings per share amounted to -0,37 SEK.



## Significant events during the first quarter

### Presentation during the American Urology Association Annual Meeting

In January, the Company announced that the results of the study conducted by the University Hospital in Uppsala have been selected for presentation during the AUA, American Urology Association Annual Meeting 2022, one of the largest and most important gatherings for urologists in the world, which takes place in New Orleans on 13- May 16 This is an important step in the upcoming launch of Prostatype® in the US market.

### Use period for Prostatype Genomics warrants of series TO 1 begins

The exercise period for the TO 1 series warrants issued in connection with Prostatype Genomics' issue of units in September 2020 began on 27 January 2022. The exercise period lasted until 17 February 2022.

### Outcome in option redemption

On February 17, 2022, the exercise period for Prostatype Genomics warrants of series TO 1 ended, which was issued in connection with the Company's issue of units in September 2020. A total of 14,841 warrants of series TO 1 were exercised.

### Establishes subsidiaries in the USA

In March, Prostatype Genomics announced that the Company is establishing a subsidiary in the United States, Prostatype Genomics, Inc., owned 100% by Prostatype Genomics AB. The establishment of the subsidiary is an important step in the work towards the US market entry.

### First order to the UK

In March, the Company announced that Cambridge Clinical Laboratories (CCL), Prostatype Genomics' partner in the United Kingdom and Ireland, has placed the first order for the Company's genetic test, Prostatype®. This means that Prostatype Genomics has taken another step in the commercialization process in another priority market.

## Significant events after the end of the period

### **Prostatype Genomics begins collaboration with the Capio Specialist Center in Solna with immediate effect.**

In April, Prostatype Genomics announced that the Company will begin cooperation with the Urology Clinic Capio Specialist Center in Solna. This collaboration means that patients and doctors can have access to the Prostatype® genetic test and a better basis for decision-making in the choice of treatment for prostate cancer.

### **The Board proposes to the Annual General Meeting to authorize the Board to decide on a rights issue in order to intensify the launch of the Prostatype® genetic test**

In May, the Board of Prostatype Genomics announced that the Company has decided to propose to the next Annual General Meeting to authorize the Board to decide on the implementation of a rights issue of units of initially approximately SEK 22.5 million before issue costs, followed by an additional approximately SEK 22.5 million before issue costs attributable to attached warrants. It is also proposed that the public be given the opportunity to participate. The initial part of the Rights Issue is covered to approximately 100 percent by subscription and guarantee commitments.

The rights issue is proposed to be able to finance and intensify the launch of Prostatype® in the USA and EMEA and to initiate and complete a number of validation studies in selected European markets as well as in the USA and Asia

## CEO comments

After leaving a developing and challenging 2021 behind us, the first quarter of 2022 has now passed. Despite a pandemic that has marked our first time as a listed company on First North, I am proud of the expansion we have succeeded in and the important milestones we have achieved for our continued development. The beginning of 2022 has been strong for Prostatype Genomics, and I look back on the last few months as a solid foundation for our continued work.

We continue to strive to strengthen our international presence, a step in that direction is that we will present at the American Urology Association Meeting 2022 in New Orleans on May 13-16. During the meeting, we will present the clinical study with Prostatype® that was conducted at the University Hospital in Uppsala, and we are very proud to have been selected to participate in one of the largest and most important meetings for urologists in the world. It is a clear proof of the strength of Prostatype®, and also an excellent opportunity for us to meet leading American urologists and decision makers. Another important step in our entry into the US market is that we have recently established a fully owned subsidiary in the US, Prostatype Genomics, Inc.

I am proud of the great progress we have already made in the United States, and it is with satisfaction that I can state that we are continuing to perform according to our timetable.

International collaboration agreements are of course important for our continued international expansion, and I have previously talked about the important agreement we have entered into with the leading British laboratory company, Cambridge Clinical Laboratories (CCL). During the past quarter, CCL placed the first order for Prostatype®, thus marking another important step in our commercialization process in one of our priority markets.

With these successes behind us, we strive to further accelerate our priority activities. To help achieve that, the Board of Directors in May proposed that the Annual General Meeting authorize the Board to decide on the implementation of a rights issue of units initially of approximately SEK 22.5 million before issue costs, followed by an additional approximately SEK 22.5 million before issue costs through attached warrants. The purpose of the rights issue is to finance and intensify the launch of Prostatype® in the USA and priority European markets

We are now continuing to work with the foundation we laid at the beginning of the year, and I look forward to another year of expansion and continued work with existing and new partners, customers, and patients.

It is clear that there is a great demand for Prostatype® in the markets we prioritize, and I am expecting to reach many exciting collaborations with caregivers during the year.

Finally, I would like to thank employees, partners, the board and our shareholders who are part of Prostatype Genomics' journey. We have an exciting time ahead of us!

**Fredrik Persson**

**CEO Prostatype Genomics AB**

**Solna 12 May 2022**

## Financial information and comments

### Comparison between January-March 2022 and January-March 2021

#### Net sales

Net sales for the Company amounted to 261 (5) TSEK. The company is still in the initial phase of commercialization; hence sales are as expected.

#### Operating profit/loss

The operation profit/loss for the Company's first quarter 2022 amounted to -5 536 (-3 394) TSEK which is a decrease with approximately 39 % in comparison to prior period. The company's costs consist mainly of commercialization, testing and staff.

#### Cash flow from current operations

The cash flow for the first quarter amounted to - 5 903 (- 5 342) TSEK. The cash flow from current operations amounted to -5 803 (-4 514) TSEK. The cash flow for the period is in line with the Company's operating expenses.

#### Cash flow from investment activities

The cash flow from investment activities amounted to 0 (-795) TSEK. From the start of 2022 all product development is carried as expense.

#### Cash flow from financing activities

The cash flow from financing activities amounted -100 (-33) TSEK. Liquid funds as of 31<sup>st</sup> March 2022 amounted to 20 329 (10 520) TSEK.

#### Number of shares

On March 31<sup>st</sup>, 2022, the number of shares was 15 103 602 (13 186 870). The nominal increase is assignable to the TO1 series of warrants and a share issue carried through 2021. Average amount of shares during the first quarter 2022 was 15 096 182.

## Prostatype Genomics business and financial ratios

Amounts in SEK	2022-01-01	2021-01-01	2021-01-01
	2022-03-31	2021-03-31	2021-12-31
Operating margin	neg	neg	neg
Profit margin	neg	neg	neg
Return on equity	neg	neg	neg
Equity/debt ratio	74%	79%	49%
Equity capital	30 350 773	24 867 987	35 905 840
Cash flow	-5 902 576	-5 342 025	4 467 387
Number of shares (end of the period)	15 103 602	186 031	15 088 761
Number of shares (average for the period)	15 096 182	186 031	102 082
Number of shares - full dilution (end of the period)	15 145 458	186 031	102 082
Earnings per share	-0,37	-18,40	-1,04
Diluted earnings per share (end of the period)	-0,37	-18,40	-1,02
Number of employees (end of the period)	5	5	6
Dividend per share	-	-	-

### Definition of key ratios

Operating margin	Operating profit/loss after depreciation / net sales
Profit margin	Net profit/loss for the year / net sales
Return on equity	Profit/loss before tax / adjusted equity
Equity/debt ratio	Adjusted equity / total assets
Earnings per share	Net profit/loss for the year / number of shares by period closing
Diluted earnings per share (end of the period)	Net profit/loss for the year / (number of shares + warrants by period closing)

## Financial statement

Amounts in SEK	2022-01-01	2021-01-01	2021-01-01
	2022-03-31	2021-03-31	2021-12-31
Net sales	260 760	4 998	10 001
Own work capitalized	-	794 915	2 499 641
Other operating income	3 299	12 186	12 186
<b>Total revenue</b>	<b>264 058</b>	<b>812 099</b>	<b>2 521 828</b>
<b>Operating expenses</b>			
Research and development cost	-673 447	-187 948	-1 488 110
Other external cost	-2 508 850	-2 360 462	-8 491 058
Staff cost	-2 132 297	-1 622 404	-7 980 680
Depreciation, amortization and impairment	-486 282	-22 121	-88 483
Other operating expenses		-13 600	-21 762
<b>Operating profit/loss</b>	<b>-5 536 818</b>	<b>-3 394 435</b>	<b>-15 548 265</b>
<b>Income after financial items</b>			
Interest expenses and similiar items	-	-	
Interest expenses and similiar items	-18 250	-27 936	-81 493
<b>Profit/loss after financial items</b>	<b>-5 555 067</b>	<b>-3 422 371</b>	<b>-15 629 758</b>
<b>Profit or loss before tax</b>	<b>-5 555 067</b>	<b>-3 422 371</b>	<b>-15 629 758</b>
<b>Total profit/loss for the period</b>	<b>-5 555 067</b>	<b>-3 422 371</b>	<b>-15 629 758</b>



## Balance sheet

(SEK)	2022-03-31	2021-03-31	2021-12-31
<b>ASSETS</b>			
<b>Fixed assets</b>			
<i>Intangible assets</i>			
Capitalized development expenditure	18 102 203	16 861 637	18 566 363
Patent	18 587	92 939	37 175
<b>Total intangible assets</b>	<b>18 120 790</b>	<b>16 954 576</b>	<b>18 603 538</b>
<i>Property, plant and equipment</i>			
Plant and machinery			
Equipment and tools	10 555	24 686	14 089
<b>Total property, plant and equipment</b>	<b>10 555</b>	<b>24 686</b>	<b>14 089</b>
<b>Total fixed assets</b>	<b>18 595 505</b>	<b>16 979 262</b>	<b>18 617 627</b>
<b>Current assets</b>			
<i>Inventory</i>			
Finished products	74 560	326 219	107 520
Advances to suppliers	84 506	28 578	74 506
<b>Total current assets</b>	<b>159 066</b>	<b>354 797</b>	<b>182 026</b>
<i>Current receivables</i>			
Accounts receivable	403 136	146 573	146 573
Other receivables	664 001	379 361	502 980
Prepaid expenses and accrued income	376 901	290 729	424 429
<b>Total current receivables</b>	<b>1 444 038</b>	<b>816 663</b>	<b>1 073 982</b>
<i>Current investments</i>			
Other current investments	10 500 000		10 500 000
<b>Total current investments</b>	<b>10 500 000</b>		<b>10 500 000</b>
<i>Cash and bank</i>			
	3 926 599	10 519 763	9 829 175
<b>Total current assets</b>	<b>16 029 704</b>	<b>11 691 222</b>	<b>21 585 183</b>
<b>TOTAL ASSETS</b>	<b>34 161 049</b>	<b>28 670 484</b>	<b>40 202 810</b>

## Balance sheet

(SEK)	2022-03-31	2021-03-31	2021-12-31
<b>EQUITY AND LIABILITIES</b>			
<b>Total equity</b>			
<b>Restricted equity</b>			
Share capital	905 326	791 212	905 326
New share issue under registration	18 566 363	16 861 637	18 566 363
Development fund	19 471 689	17 652 849	19 471 689
<b>Total restricted equity</b>			
<b>Non-restricted equity</b>	130 452 900	107 321 774	130 452 900
Share premium reserve	-114 018 748	-96 684 264	-98 388 990
Profit/loss brought forward	-5 555 067	-3 422 371	-15 629 758
<b>Total non-restricted equity</b>	10 879 084	7 215 138	16 434 152
<b>Total equity</b>	30 350 773	24 867 987	35 905 840
<b>Long-term liabilities</b>	-	-	-
Convertible loan	866 667	1 066 667	866 667
Other debt to credit institutions	866 667	1 066 667	866 667
<b>Total long-term liabilities</b>			
<b>Current liabilities</b>	300 000	366 667	400 000
Debt to credit institutions	620 489	1 135 147	1 174 708
Accounts payable	123 480	77 204	176 876
Tax liabilities	294 250	57 564	212 175
Other current liabilities	1 605 390	1 099 249	1 466 544
Accrued liabilities and deferred income	2 943 609	2 735 830	3 430 303
<b>Total current assets</b>			
<b>TOTAL EQUITY AND LIABILITIES</b>	34 161 049	28 670 484	40 202 810

## Cash flow statement

(SEK)	2022-01-01	2021-01-01	2021-01-01-
	2022-03-31	2021-03-31	2021-12-31
<b>Operating activities</b>			
Profit after financial items	-5 555 067	-3 422 371	-15 629 758
Adjustments for items not included in cash flow etc	486 282	22 121	88 483
<b>Cash flow from operating activities before changes in working capital</b>	<b>-5 068 785</b>	<b>-3 400 250</b>	<b>-15 541 275</b>
<b>Cash flow from changes in working capital</b>			
Change in inventory	22 960	40 150	212 921
Change in operating receivables	-370 056	382 799	125 480
Change in operating liabilities	-386 694	-1 536 476	-875 336
<b>Cash flow from current operations</b>	<b>-5 802 576</b>	<b>-4 513 777</b>	<b>-16 078 211</b>
<b>Investment activities</b>			
Acquisition of intangibles		-794 915	-2 499 641
Acquisition of fixed assets	0	0	0
<b>Cash flow from investment activities</b>	<b>0</b>	<b>-794 915</b>	<b>-2 499 641</b>
<b>Financing activities</b>			
Paid-in option premium	0	0	0
Net issue liquidity incl. bridge loan	0	0	23 245 239
Received convertible loans	0	0	0
Amortization	-100 000	-33 333	-200 000
<b>Cash flow from financing activities</b>	<b>-100 000</b>	<b>-33 333</b>	<b>23 045 239</b>
<b>Cash flow for the period</b>	<b>-5 902 576</b>	<b>-5 342 025</b>	<b>4 467 387</b>
<b>Opening liquid funds</b>	<b>20 329 175</b>	<b>15 861 788</b>	<b>15 861 788</b>
<b>Closing liquid funds</b>	<b>14 426 599</b>	<b>10 519 763</b>	<b>20 329 175</b>

## Changes in equity

### 1 January 2021 – 31 December 2021

SEK	Share capital	New share issues in progress	Development fund	Share premium reserve	Accumulated profit/loss
Opening balance	791 212		16 066 722	107 321 774	-95 889 349
New share issue	114 113			24 610 470	
Expenses of the issue				-1 479 344	
Option premium					
Transfer to development fund			2 499 641		-2 499 641
Result for the period					-15 629 758
<b>Closing balance</b>	<b>905 325</b>	<b>-</b>	<b>18 566 363</b>	<b>130 452 900</b>	<b>-114 018 748</b>

### 1 January 2022 – 31 March 2022

SEK	Share capital	New share issues in progress	Development fund	Accumulated profit/loss
Opening balance	905 325	18 566 363	130 452 900	-114 018 748
Result for the period				-5 555 067
<b>Closing balance</b>	<b>905 325</b>	<b>18 566 363</b>	<b>130 452 900</b>	<b>-119 573 815</b>

## General information

### Company information

Prostatype Genomics AB with organization number 556726-0285 is a limited company registered in Sweden, domiciled in Stockholm. The address is Industrivägen 19, 171 48 Solna. The company is engaged in the research and developments of medical devices.

In this report, Prostatype Genomics AB is called either by its full name or as “the Company”, alternatively as Prostatype. All figures in the report are in thousands of Swedish kronor (TSEK) if not otherwise specified.

The Company is the result of more than ten years of research into the genomics of prostate cancer. The Company was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market ready product Prostatype® Test System. Prostatype® is a test for diagnosis and prognosis that has been developed to provide the complementary information that is often needed for the selection of the optimal treatment strategy for each patient. The test analyzes the gene expression in cancer cells from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed. Aided by AI (Artificial Intelligence) technology, the gene test of Prostatype Genomics makes it possible to make a better prognosis and to classify the patient’s illness into different risk types. In that way the Company can reduce the risk of over- or under treatment, which in many cases lead to great discomfort for the patient. Prostatype® is today the only gene test for prostate cancer that is available in kit format. The product is also very scalable in terms of volume due to the algorithm that forms the basis of the test.

### Accounting principles

The year-end report has been prepared in accordance with) BFNAR 2012:1 Årsredovisning och koncernredovisning (K3) issued by the Swedish Accounting Standards Boards (BFN). The accounting policy for the Company complies with applied accounting principles for the most recent published annual report.

### Covid-19

Compared with the previous financial year, the effects of the Covid-19 pandemic subsided during the quarter. However, in some markets it continues to make access to healthcare professionals more cumbersome that would otherwise be the case.

### War in Ukraine

The Company has not experienced any effects of the ongoing war in Ukraine.

### Related party transactions

During the period from January to March 31 2022, except for what is detailed below, no related party transactions have taken place.

Several of the bridge loans that were made during 2020 constitute related party transactions. The related parties who made bridge loans to Prostatype Genomics in connection to the bridge financing are presented below.

The Company has procured services for in total 61 500 SEK from the company SecureAppbox AB during the period. SecureAppbox AB is a supplier of web-based solutions for P-score. Håkan Englund, Member of the Board of Prostatype Genomics AB, is the Chairman of the Board of SecureAppbox. Håkan Englund has not taken part in the procurement process for these services.

Transactions with related parties have been performed on market terms.

### Risk factors

For a description of the most significant market- and operational risk, please see the recently published Annual Report for 2021.

## Other information

### Dates for publication of financial information

General Meeting 2021	2022-06-02
Q2 Report	2022-08-18
Q3 Report	2022-11-10
Q4 & Year-end Report	2023-02-16

This interim report, as well as further information, is available at Prostatype Genomics' web page, [www.prostatypegenomics.com](http://www.prostatypegenomics.com)

### Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, [ca@skmg.se](mailto:ca@skmg.se).

### Review of interim report

This interim report has not been subject to review by the Company's auditors

### Publication

*This information is such information that Prostatype Genomics AB, from the time of listing, is obliged to publish in accordance with the EU market abuse regulation. The information is published by the below contact person, for publication on May 12, 8.00 AM. All information is given also in a Swedish version, and in case of any discrepancies, the Swedish version prevails.*

.

Fredrik Persson, VD, 073-049 77 01, [fredrik.persson@prostatypegenomics.com](mailto:fredrik.persson@prostatypegenomics.com)

This interim report gives an accurate overview of the Company's operations, financial status, and results

Solna 12 May 2022

---

Anders Lundberg  
Chairman

---

Håkan Englund  
Director

---

Michael Häggman  
Director

---

Karlheinz Schmelig  
Director

---

Fredrik Persson  
CEO



**Prostatype Genomics AB**

Industrivägen 19, SE-171 48 Solna

Telefon:

+46 (0)8-20 87 00

Hemsida:

[www.prostatypegenomics.com](http://www.prostatypegenomics.com)